![ヨドバシ.com - マムート MAMMUT Saentis Low Men 3030-03990 00467 bright white UK11(29.5cm) [ハイキングシューズ メンズ] 通販【全品無料配達】 ヨドバシ.com - マムート MAMMUT Saentis Low Men 3030-03990 00467 bright white UK11(29.5cm) [ハイキングシューズ メンズ] 通販【全品無料配達】](https://image.yodobashi.com/product/100/000/001/005/046/944/100000001005046944_10203.jpg)
ヨドバシ.com - マムート MAMMUT Saentis Low Men 3030-03990 00467 bright white UK11(29.5cm) [ハイキングシューズ メンズ] 通販【全品無料配達】
![Slug and Vimentin downregulation at the metastatic site is associated with Skip-N2 metastasis of lung adenocarcinoma | SpringerLink Slug and Vimentin downregulation at the metastatic site is associated with Skip-N2 metastasis of lung adenocarcinoma | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12672-022-00467-4/MediaObjects/12672_2022_467_Fig3_HTML.png)
Slug and Vimentin downregulation at the metastatic site is associated with Skip-N2 metastasis of lung adenocarcinoma | SpringerLink
![Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer | npj Breast Cancer Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer | npj Breast Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41523-022-00467-1/MediaObjects/41523_2022_467_Fig1_HTML.png)
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer | npj Breast Cancer
![Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer | npj Breast Cancer Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer | npj Breast Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41523-022-00467-1/MediaObjects/41523_2022_467_Fig2_HTML.png)